🔗 Share this article

Given that the US proceeds with unprecedented changes to its immunization recommendations, an unexpected name has surfaced somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by casting doubt on coronavirus vaccines in the pandemic and has focused upon alleged fatalities following Covid immunization in her recent tenure at the FDA.

Proposed Shifts to Pediatric Immunization Program

Agency leaders had intended to announce radical changes to the pediatric vaccination calendar in December, synchronizing the US with the Danish vaccine program, according to reports – a substantial departure that would put the US at odds with much of the global community with little proof for benefit. This reveal has been pushed back until the new year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to speak at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth individual to head the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a closer partnership between the drug and vaccine divisions as Høeg and Prasad strengthen their influence at the agency – and it signals a increased emphasis upon rolling back long-standing immunizations at the FDA.

The new acting director has repeatedly called for discontinuing specific childhood shot schedules in the US so as to align more in line with Denmark, a nation with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccines – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – rather than medication approval.

Concerns Over Expertise

The appointee has little discernible experience in medication creation, oversight or administrative roles, which has been typical for past directors of the CBER. She has served at the FDA as a senior adviser to the agency head and CBER since March.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous commissioners of CBER would “grasp regulatory frameworks and the research of pharmaceutical innovation”, said Janet Woodcock. “Objectively, she lacks the sort of resume that previous people who ran the center have had.”

The drug center has an enormous range of responsibilities at the agency, Woodcock emphasized.

“Everybody just focuses on the new drug program, but the generic drug division clears numerous generic medications. There’s a biosimilars division, OTC medication office and more, and every single one have to be supervised,” she noted. “The area you neglect, that’s the thing that I always told people is going to cause problems.”

Furthermore, a significant management component to the role, which supervises in excess of 5,000 staff members. “It’s a enormous management job, if you perform it correctly,” the former official added.

Official Statement and Contentious Initiatives

In response to concerns about Høeg’s fitness for the role and whether this assignment signifies more teamwork among FDA leaders on vaccines, a press secretary responded that the “concerns rely on inaccurate assumptions”.

“Her experience aligns with the responsibilities of her job,” the official said, noting the months Dr. Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a disputed expedited medication authorization process that apparently worried her preceding directors. “By what process are these drugs being chosen for this voucher program? Who is making the decisions?” Howard questioned. “There’s a lot of confidentiality happening at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA appears to be shifting towards more relaxed oversight of pharmaceuticals, with the exception of shots.”

Documented Track Record on Vaccines

With immunizations, Høeg has a more established, if concerning, track record, critics observe. She authored a study using non-validated public submissions to determine the rate of heart inflammation following Covid immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the new federal leadership encompassed changing guidelines for novel immunizations and halting “unnecessary” immunizations, she remarked post-election on a online show. At the FDA, Dr. Høeg has allegedly proposed barring adolescent males from obtaining COVID-19 vaccinations.

“She is an complete true believer who begins with her preconceived notions and reverse-engineers to fit the data in a highly disingenuous, untruthful manner,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of other skeptics, {like|